News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Brian Ellman, MBA

Articles by Brian Ellman, MBA

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy

ByGirishanthy Krishnarajah, MPH, MBA/MS, PhD,Jee-Yeon K. Lehmann, PhD,Brian Ellman, MBA,Rachel H. Bhak, MS,Maral DerSarkissian, PhD,Deane Leader, Jr, PhD, MBA,Ann L. Bullinger, PharmD,Mei

October 21st 2016

Latest Updated Articles

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
October 21st 2016

Trending on AJMC

COVID Is Back in the Bay Area: Is It the XFG "Stratus" Variant?

Zanubrutinib Outlasting Acalabrutinib in CLL

FDA Clears Lerodalcibep-Liga Autoinjector, Widens LDL-C Indication

Atlanta Panel Confronts Bottlenecks in Alzheimer Disease Diagnosis and Care

Experts Weigh Vitiligo's Cosmetic Label as Oral Therapies Near